Should I Buy SBFM? SBFM 2026 Analysis

Should You Buy Sunshine Biopharma Inc (SBFM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.200

1 Day change

4.35%

52 Week Range

3.900

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SBFM is not a good buy right now for an impatient investor looking for immediate upside. The primary trend remains bearish (SMA_200 > SMA_20 > SMA_5), profitability is deteriorating despite revenue growth, and there are no near-term news catalysts. With no proprietary buy signals today, the risk/reward is unfavorable at the current price (~1.215) sitting just above key support (1.208).

Technical Analysis

Price/Trend: The chart structure is bearish with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling a prevailing downtrend. Momentum: MACD histogram is slightly positive (0.00652) but is positively contracting, which suggests bullish momentum is weakening rather than strengthening. RSI: RSI_6 at 38.764 is neutral-to-weak (not oversold), implying there is room for further downside before a mean-reversion setup becomes compelling. Levels: Immediate support is S1 = 1.208 (current price ~1.215 is very close). A break below 1.208 increases downside risk toward S2 = 1.172. Upside levels to reclaim for a more credible reversal are Pivot = 1.265 and R1 = 1.322.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Positive Catalysts

- Hedge funds are reported as net buyers with buying amount up 11812.88% over the last quarter (strong sentiment indicator, albeit without size/context).
- Pattern-based projection indicates a modest positive bias (reported 80% chance of small gains), supporting the possibility of a short-term bounce if support holds.
- MACD remains marginally above zero, suggesting downside momentum is not aggressively accelerating at this moment.

Neutral/Negative Catalysts

- Insider activity is neutral (no supportive insider-buying signal).

Financial Performance

Latest quarter: 2025/Q3. Revenue increased to 9,417,179 (+11.64% YoY), showing top-line growth. However, profitability weakened: Net Income fell to -883,820 (down -26.21% YoY), EPS declined to -0.19 (down -79.79% YoY), and Gross Margin dropped to 31.62 (down -4.79% YoY). Overall, growth is present, but operating performance and margins are deteriorating, which is a negative setup for near-term buying without a clear catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no observable recent trend in Wall Street upgrades/downgrades or target revisions. As a result, there is no clear pro/con consensus signal from analysts in the supplied dataset.

Analyst Rating

Wall Street analysts forecast SBFM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBFM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold